Skip to content
JournalsWorldThe Global Research Discovery Platform
Login Sign Up
SCHOLARLY PUBLICATION

De-novo and acquired resistance to immune checkpoint targeting

Nicholas L. X. Syn, Michele W.L. Teng, Tony S.K. Mok, Ross Andrew Soo

📖 The Lancet Oncology → 📅 2017-12-01 🔗 DOI: 10.1016/s1470-2045(17)30607-1
View Journal Profile → View Official Paper ↗

📄 Abstract

The abstract has not yet been added. Use the official source link for the complete publication record.

🔬 Related Research Papers

The Lancet Oncology

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

Helena Linardou, Issa J Dahabreh et al. 2008-09-18 · Read paper → The Lancet Oncology

Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study

Thomas Bachelot, Gilles Romieu et al. 2012-11-01 · Read paper → The Lancet Oncology

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim S. Fizazi et al. 2013-01-08 · Read paper → The Lancet Oncology

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

Robert John Motzer, Bernard J. Escudier et al. 2013-04-17 · Read paper → The Lancet Oncology

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz et al. 2016-10-22 · Read paper → The Lancet Oncology

Increasing incidence of colorectal cancer in Asia: implications for screening

Joseph J.�Y. Sung, James Lau et al. 2005-11-01 · Read paper → The Lancet Oncology

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

Takashi Seto, Terufumi Kato et al. 2014-08-27 · Read paper → The Lancet Oncology

Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study

Brian P O'Sullivan, Shao Hui Huang et al. 2016-02-27 · Read paper → The Lancet Oncology

Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial

Robert I. Haddad, Anne O’Neill et al. 2013-02-12 · Read paper → The Lancet Oncology

Depression and anxiety in long-term cancer survivors compared with spouses and healthy controls: a systematic review and meta-analysis

Alex J. Mitchell, David W Ferguson et al. 2013-06-04 · Read paper → The Lancet Oncology

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp et al. 2014-07-14 · Read paper → The Lancet Oncology

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

Thomas Powles, Elizabeth R. Plimack et al. 2020-10-23 · Read paper →